April 29, 2023 Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Read press release
March 28, 2023 MedinCell announces the initiation of coverage of its stock by Portzamparc – BNP Paribas Group Read press release
February 23, 2023 MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company Read press release
January 24, 2023 Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK) Read press release
January 5, 2023 MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population Read press release
